Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | EU101 |
| Synonyms | |
| Therapy Description |
EU101 is an agonistic monoclonal antibody that targets CD137 (4-1BB; TNFRSF9), resulting in increased CD137 signaling and potentially leading to inhibition of T-regulatory cells and induction of a cytotoxic T-lymphocyte (CTL)- and NK cell-mediated antitumor response, resulting in tumor cell killing (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| EU101 | EU 101|EU-101 | TNFRSF9 Antibody 36 | EU101 is an agonistic monoclonal antibody that targets CD137 (4-1BB; TNFRSF9), resulting in increased CD137 signaling and potentially leading to inhibition of T-regulatory cells and induction of a cytotoxic T-lymphocyte (CTL)- and NK cell-mediated antitumor response, resulting in tumor cell killing (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04903873 | Phase Ib/II | EU101 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |